Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Father Flanagan's Boys' Home | OTHER |
Not provided
Not provided
Not provided
Not provided
A pharmacoimaging study of oxytcoin in antisocial personality disorder and psychopathy
Using a double-blinded, placebo controlled design, we explored similarities and differences in i) an important component of empathic processing (neural response to facial emotional expressions) and ii) decision-making in violent men with ASPD+/-Psychopathy, compared to healthy non-offenders (NO; n= 21 across studies), with placebo and after acute application of intranasal oxytocin, using functional Magnetic Resonance Imaging (fMRI).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Violent offenders with psychopathy | Other | Violent offenders with psychopathy |
|
| Violent offenders without psychopathy | Other | Violent offenders without psychopathy |
|
| Healthy non-offenders | Other | Healthy non-offenders |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Oxytocin nasal spray | Drug | Intranasal spray containing 40 IU of oxytocin |
|
| Measure | Description | Time Frame |
|---|---|---|
| Within-group effect of oxytocin on nerual modulation of fear | Differences in responsivity to morphed faces on FMRI in oxytocin vs fear condition- clusterwise analysis using AFNI (effect size is beta values) | 10 minutes |
| Measure | Description | Time Frame |
|---|---|---|
| Baseline neural modulation of morphed fearful faces | Response to morphred faces on FMRI in placebo condition- clusterwise analysis using AFNI (effect size is beta values) | 10 minutes |
Not provided
Inclusion Criteria:
Violent offenders:
Offenders with convictions for violent crimes (murder, rape, attempted murder, grievous and actual bodily harm) who met DSM-5 criteria for antisocial personality disorder (Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5 PD) Psychopathy or non-psychopathy subgroup based on Psychopathy Checklist- Revised (PCL-R; (Hare, 2003))- score of 25 as the threshold for psychopathy in this English population.
Healthy non-offenders:
Non-offenders with no personality disorder
Exclusion criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nigel Blackwood, MB MD | King's College London | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Insititue of Psychiarty, Psychology and Neuroscience | London | Nottinghamshire | SE58AF | United Kingdom |
This was not built into original ethical protocol due to concerns about sensitivity of data.
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | May 1, 2017 | May 15, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000987 | Antisocial Personality Disorder |
| ID | Term |
|---|---|
| D010554 | Personality Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Double-binded placebo-controlled crossover trial
Not provided
Not provided
Double-blinded- participant and investigator.
| Placebo spray | Other | Application of inert placebo, identical in odor, color, and droplet size except for absence of oxytocin |
|